Becton Dickinson & CO 8-K filings

Becton, Dickinson and Company announced robust third-quarter fiscal 2026 financial results, exceeding expectations with significant revenue growth and a notable increase in cash flow, leading to an upward revision of full-year earnings per share guidance.

Becton, Dickinson and Company announces the upcoming retirement of EVP Michael Garrison, with the BioPharma Systems segment to report directly to the CEO.

Becton, Dickinson and Company has resumed U.S. shipments of ChloraPrep following successful completion of additional final release testing.

Becton, Dickinson and Company's subsidiary issued 600 million in 3.855% notes due 2033 to refinance existing debt.

Becton, Dickinson and Company announces the permanent appointment of Vitor Roque as Executive Vice President and Chief Financial Officer, effective May 7, 2026, following his tenure as interim CFO.

Becton, Dickinson and Company announced robust second quarter fiscal 2026 financial results, exceeding expectations with revenue growth and adjusted diluted EPS, leading to an upward revision of full-year EPS guidance.

Becton, Dickinson and Company announced amendments to its bylaws on April 28, 2026, primarily updating advance notice provisions for contested elections.

Becton, Dickinson and Company announced that Executive Vice President Richard (Rick) Byrd intends to retire after nearly 25 years with the company, remaining in his role through June.

Becton, Dickinson and Company has released recast historical financial information following the February 2026 spin-off of its Biosciences and Diagnostic Solutions business.

Becton, Dickinson and Company successfully increased its cash tender offer for outstanding debt securities to $2 billion, with early results showing strong participation and proration for certain notes.

Becton, Dickinson and Company announced tender offers to repurchase up to $1.6 billion of its outstanding debt securities for cash.

Becton, Dickinson and Company announced the successful completion of the spin-off of its Biosciences & Diagnostic Solutions business and its combination with Waters Corporation, receiving $4 billion in cash and distributing Waters common stock to shareholders.

Becton, Dickinson and Company announced stronger-than-expected first-quarter fiscal 2026 financial results and expects to complete the combination of its Biosciences and Diagnostic Solutions business with Waters Corporation today.

Becton, Dickinson and Company issued Series D Preferred Stock to trusts as a procedural step for its anticipated spin-off of Augusta SpinCo Corporation and Reverse Morris Trust transaction with Waters Corporation.

Becton, Dickinson and Company has reorganized its business into five new segments and announced the future divestiture of its Life Sciences segment.

Becton, Dickinson and Company approved a new executive severance plan and increased its equity compensation pool by 3.935 million shares following shareholder approval.

Becton, Dickinson and Company announced a temporary blackout period for its 401(k) plan due to a pending transaction with Waters Corporation.

Becton, Dickinson and Company filed an amendment to its 8-K to disclose restricted stock unit compensation for newly elected board members Robert L. Huffines and Jacqueline Wright.

Becton, Dickinson and Company announced the election of Robert L. Huffines and Jacqueline Wright to its Board of Directors, effective December 1, 2025, expanding the board to fourteen members.

Becton, Dickinson and Company announced robust financial results for its fiscal 2025 fourth quarter and full year, driven by organic growth and significant margin expansion, while also providing its fiscal 2026 outlook.

Becton, Dickinson and Company announced its CFO's departure and provided preliminary unaudited revenue results for its fourth quarter and full fiscal year 2025.

Becton, Dickinson and Company has entered into a new $2.75 billion senior unsecured revolving credit facility, enhancing its financial flexibility for general corporate purposes.

Becton, Dickinson and Company announced robust third fiscal quarter 2025 results, exceeding revenue and earnings expectations and raising its full-year adjusted diluted EPS guidance.

Becton, Dickinson and Company (BD) has entered into definitive agreements to separate its Biosciences and Diagnostic Solutions business, which will then merge with Waters Corporation in a Reverse Morris Trust transaction, resulting in BD shareholders owning 39.2% of Waters and BD receiving approximately $4 billion in cash.

Becton, Dickinson and Company and Waters Corporation have entered into a definitive agreement to combine BD's Biosciences & Diagnostic Solutions business with Waters in a $17.5 billion Reverse Morris Trust transaction, creating a new life science and diagnostics leader.

Becton, Dickinson and Company (BD) has announced a proposed settlement of consolidated stockholder derivative actions, including a $9 million payment funded by D&O insurance and the implementation of new corporate governance modifications.

Becton, Dickinson and Company amended its bylaws to update procedures and disclosure requirements for shareholder nominations and business at annual meetings, aligning with SEC Rule 14a-19.

Becton Dickinson announced its Q2 fiscal year 2025 results, reporting a revenue increase of 4.5% and updating its full-year fiscal 2025 guidance to reflect tariff impacts.

Becton, Dickinson and Company (BD) has elected Gregory J. Hayes to its Board of Directors, effective March 26, 2025, increasing the board size to twelve members.

Becton, Dickinson and Company (BD) reports better-than-expected Q1 fiscal 2025 results and unveils plans to separate its Biosciences and Diagnostic Solutions business to unlock value and enhance strategic focus.